The cancer drugs & treatments market data, analysis by infomed asia









News

News in Focus

Business & Money

Solutions

Journalis ts

Blog

Resources

Science & Tech

Lifestyle & Health

Se nd a Re le as e

Policy & Public Interest



People & Culture

The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023' Nov 21, 2013, 11:04 ET f rom Reportlinker















NEW YORK, Nov. 21, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Journalists and Bloggers

T he Cance r D rug s & T re at me nt s Marke t - D at a, Analys is & Fo re cas t s t o 20 23'

The news you need, when you need it.

http://www.reportlinker.com/p01889380/The-Cancer-Drugs--Treatments-Market---Data-Analysis-Forecasts-to2023'.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

GMR Data forecast that the global cancer drugs and treatments market will reach $143.7bn by 2023. GMR Data's latest report 'T he Cance r D rug s & T re at me nt s Marke t - D at a, Analys is & PDFmyURL lets you convert a complete website to PDF automatically!

Fo re cas t s t o 20 23' explains just how this market will experience growth over the medium and long term. The report also highlights forecast for the next 5 and 10 years, so that you and your company can make speciﬁc long term plans. Don't let your competitors get the head-start on you, order this report today.

Have yo u s e e n t he re ce nt ne ws o n Cance r D rug s? - Merck's new cancer drug kept more than 4 of 5 melanoma patients alive for a year - Biopharma Alliances will be needed For Cancer Drugs in the cost conscious future – Forbes - EU approval for Bayer's prostate cancer drug - Sanoﬁ ditches late-stage bone marrow cancer drug

The Anti-cancer treatment market is already worth $77.4bn (GMR Data) and continues to be one of the largest and fastest growing areas for new drug development – can you aﬀ ord not to be involved? Should you and your company be capturing a greater market share?

Es s e nt ial f act s e xamine d in t his re p o rt

Join PR Newswire for Journalists to access all of the free services designated to make your job easier. In need of subject matter experts for your story? Submit a free Prof Net request and ﬁnd the sources you need.

1) Across 2013, 15 new molecular entities were approved by the FDA; out of which seven were for Oncology. 2) Currently targeted therapies dominate the oncology pipeline, followed by chemotherapy. 3) Immunotherapy drugs are gaining increasing amounts of attention due to fewer expected side eﬀ ects.

Only by ordering this in-depth exclusive report will you have full access to the unique ﬁndings. This information is not available anywhere else. Find full details of these approved drugs alongside key cancer drugs in their testing phases in this new GMR Data report. PDFmyURL lets you convert a complete website to PDF automatically!

LEARN MORE

D is co ve r e xact ly what t he ind us t ry le ad e rs are d o ing T O DAY Within GMR Data's 'T he Cance r D rug s & T re at me nt s Marke t - D at a, Analys is & Fo re cas t s t o 20 23' we analyse the key cancer drugs and treatments in the market currently and how they will perform across the next decade.

Our study focuses on the individual revenues of the top 25 anti-cancer agents. With variable patents and the threat of generics, how will these key cancer drugs fare across the next decade? – ONLY THIS UNIQUE REPORT WILL TELL YOU

• Rituxan • Herceptin • Avastin • Gleevec • Revlimid • Alimta • Velcade

PL US – In- d e p t h co unt ry analys is – D is co ve r which co unt rie s and re g io ns will d rive t he o nco lo g y d rug s marke t t o 20 23? The US spent $322bn on healthcare in 2011, GMR Data estimate that the US spent $31.8bn in the oncology market in 2012, capturing 40.5% of the market. 2nd to the US was Japan; spending $8.9bn in 2012, capturing 11.2%. The European mainstays of the pharmaceutical sector; the UK, Germany, France, Spain & Italy equated to 25% of the global oncology market in 2012.

But how will these country's markets develop? This report will tell you - TODAY PDFmyURL lets you convert a complete website to PDF automatically!

Exclus ive Ind us t ry s o urce d inf o rmat io n, no t availab le anywhe re e ls e As well as primary and secondary research sources, GMR Data have interviewed leading cancer specialists within big pharma, R&D, wholesalers, distributors, marketeers and key clinical organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their ďŹ eld â&#x20AC;&#x201C; This information is not available anywhere else.

This GMR Data report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand development of Cancer Drugs. This report will arm you with all you and your company require to develop, price, launch and market a cancer drug.

With over 240+ pages, and over 270+ pages of charts, tables and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.

Chap t e r 1 Exe cut ive Summary 1.1. Cancer Drugs Market Review 1.2. Chapter Breakdown 1.3. Research and Analysis Methods

Chap t e r 2 T yp e s o f Cance r

2.1 Blood Cancer Types and Symptoms 2.1.2 Blood Cancer- Global Market 2.1.3 Blood Cancer- Causes and Risk Factors

PDFmyURL lets you convert a complete website to PDF automatically!

2.2 Bone Cancer Types and Symptoms 2.2.1 Bone Cancer- Global Market 2.2.2 Bone Cancer Causes and Risk Factors

2.3 Brain Cancer Types and Symptoms 2.3.1 Brain Cancer Market- Global 2.3.2 Brain Cancer- Causes and Risk Factors 2.4 Breast Cancer Types and Symptoms 2.4.1 Breast Cancer Market- Global 2.4.2 Breast Cancer Causes and Risk factors 2.5 Digestive/ Gastrointestinal Cancer Types and Symptoms 2.5.1 Gastrointestinal Cancer Market- Global 2.5.2 Gastrointestinal Cancer- Causes and Risk Factors

2.6 Endocrine Cancers Types and Symptoms 2.6.1 Endocrine Cancer Market- Global 2.6.2 Endocrine Cancer- Causes and Risk Factors

2.7 Eye Cancer Types and Symptoms 2.7.1 Eye Cancer Market- Global 2.7.2 Eye Cancer - Causes and Risk Factors

2.8 Genitourinary Cancers Types & Symptoms 2.8.1 Genitourinary Cancer Market â&#x20AC;&#x201C; Global PDFmyURL lets you convert a complete website to PDF automatically!

2.8.2 Genitourinary Cancers - Causes and Risk Factors

2.9 Gynaecologic Cancers Types & Symptoms 2.9.1 Gynaecologic Cancer Market – Global 2.9.2 Gynaecologic Cancers - Causes and Risk Factors

2.10 Head & Neck Cancers Types & Symptoms 2.10.1 Head and Neck Cancer Market – Global 2.10.2 Head and Neck Cancer - Causes and Risk Factors 2.11 Respiratory/Lung Cancers Types & Symptoms 2.11.1 Respiratory Cancer Market – Global 2.11.2 Respiratory Cancer - Causes and Risk Factors 2.12 Skin Cancers Types & Symptoms 2.12.1 Skin Cancer – Global Market 2.12.2 Skin Cancer - Causes and Risk Factors

2.13 Worldwide Cancer Facts and Statistics 2.13.1 Cancer Incidence Facts & Statistics 2.13.2 Cancer Mortality and Survival Facts & Statistics

Chap t e r 3 Cance r; Caus e s & Eﬀ e ct s 3.13 Genetic Causes 3.14 Tobacco & Smoking PDFmyURL lets you convert a complete website to PDF automatically!

3.15 Physical Activities and Eating Habits 3.16 Viral Infections 3.17 Bacterial Infections 3.18 Age 3.19 Carcinogens

Chap t e r 4 Cance r T re at me nt T yp e s & Sid e Eﬀ e ct s 4.1 Surgery 4.1.1 Potential Side eﬀ ects of Surgery

4.2 Chemotherapy 4.2.1 Major Side eff ects of Chemotherapy 4.3 Radiation Therapy 4.3.1 Major Side eff ects of Radiation Therapy 4.4 Targeted Therapy 4.4.1 Major Side eff ects of Targeted Therapy

4.5 Immunotherapy (Biologic Therapy) 4.5.1 Major Side eﬀ ects of Immunotherapy 4.6 Hormonal Therapy 4.6.1 Major Side eﬀ ects of Hormone Therapy PDFmyURL lets you convert a complete website to PDF automatically!

4.7 Hyperthermia 4.7.1 Major Side eﬀ ects of Hyperthermia

4.8 Stem Cell Transplant 4.8.1 Major Side eﬀ ects of Stem Cell Transplant

4.9 Other Therapies 4.9.1 Photodynamic Therapy 4.9.2 Side eﬀ ects of Photodynamic Therapy 4.9.3 Laser Treatment 4.9.4 Side eﬀ ects of Laser Treatment

Chap t e r 5 Cance r T he rap ie s / D rug s Marke t Fo re cas t

5.1 Global Targeted Therapy Market – 2013 -2023 5.1.1 Rituxan/MabThera by Roche 5.1.2 Herceptin (Trastuzumab) by Roche 5.1.3 Avastin (Bevacizumab) by Roche 5.1.4 Gleevec (imatinib) by Novartis 5.1.5 Velcade (Bortezomib) by Takeda (Millennium) and J&J 5.1.6 Tarceva (Erlotinib) by Roche 5.1.7 Sutent (Sunitinib) by Pﬁzer 5.1.8 Sprycel (dasatinib) by Bristol Myers Squibb 5.1.9 Nexavar (Sorafenib) by Bayer and Onyx PDFmyURL lets you convert a complete website to PDF automatically!

5.1.10 Tasigna (Nilotinib) by Novartis 5.1.11 Aﬁnitor / Votubia (Everolimus) by Novartis 5.1.12 Xgeva (Denosumab) by Amgen 5.1.13 Yervoy (ipilimumab) by Bristol-Myers Squibb 5.1.14 Erbitux (cetuximab) by Bristol-Myers Squibb

5.2 Global Chemotherapy Market – 2013 -2023 5.2.1 Alimta (Pemetrexed) by Eli Lilly 5.2.2 Xeloda (capecitabine) by Roche 5.2.3 Eloxatin (oxaliplatin) by Sanoﬁ-Aventis 5.2.4 Temodar / Temodal (temozolomide) by Merck & Co. 5.2.5 Vidaza (azacitidine) by Celgene 5.2.6 Taxotere (docetaxel) by Sanoﬁ-Aventis 5.2.7 Treanda (bendamustine hydrochloride) by Teva Pharmaceuticals

5.3 Global Immunotherapy (Biological therapy) Market – 2013 -2023

5.3.1 Revlimid (lenalidomide) by Celgene 5.3.2 Gardasil (Human Papillomavirus Quadrivalent) by Merck 5.3.3 Zometa (zoledronate) by Novartis 5.4 Global Hormone Therapy Market – 2013 -2023 5.4.1 Faslodex (Fulvestrant) Injection by AstraZeneca 5.4.2 Zoladex (Goserelin acetate implant) by AstraZeneca PDFmyURL lets you convert a complete website to PDF automatically!

5.4.3 Arimidex (anastrozole) by AstraZeneca 5.4.4 Casodex (bicalutamide) by AstraZeneca 5.4.5 Sandostatin (octreotide acetate) by Novartis

Chap t e r 6 Cance r R& D Pip e line and D rug s 6.1 R&D Pipeline 6.1.1 Oncology Drugs; Recent Approvals 6.1.2 Late Stage Cancer Drugs 6.1.3 Key Experimental Cancer Drugs Pipeline 6.1.4 Oncology Drug Pipeline â&#x20AC;&#x201C; Cancer Drugs Failures

Chap t e r 7 Majo r T re nd s & Challe ng e s in t he Glo b al Cance r D rug s Marke t 7.1 Major Trends 7.1.1 Personalised Medication 7.1.2 Increasing Cancer Threat In Low & Middle Income Countries 7.1.3 Antibody Drug Conjugates (ADC) 7.1.4 Combination Therapy 7.1.5 Key Collaborations and Alliances 7.1.6 New Drug Development 7.1.7 Immunotherapy â&#x20AC;&#x201C; to be the next Industry Driver

7.2 Major Challenges PDFmyURL lets you convert a complete website to PDF automatically!

7.2.1 Expensive Treatment 7.2.2 Biosimilars Competition 7.2.3 Generic Competition 7.2.4 Severe Side EďŹ&#x20AC; ects of Cancer Care Treatment 7.2.5 Regulatory Hurdles in Cancer Drug Approvals

Chap t e r 8 Re g io nal L and s cap e â&#x20AC;&#x201C; T he Ke y Glo b al Cance r D rug Marke t s 8.1. The US Oncology Market to 2023 8.2. The UK Oncology Market to 2023 8.3. France Oncology Market to 2023 8.4 The German Oncology Market to 2023 8.5 The Spanish Oncology Market to 2023 8.6 The Italian Oncology Market to 2023 8.7 The Japanese Oncology Market to 2023 8.8 The Rest of the World Oncology Market to 2023

Chap t e r 9 Majo r Playe rs in t he O nco lo g y Marke t 9.1 Amgen 9.2 Ariad Pharmaceutical 9.3 ASTELLAS PHARMA 9.4 AstraZeneca 9.5 Bayer healthcare pharmaceuticals 9.6 Boehringer Ingelheim PDFmyURL lets you convert a complete website to PDF automatically!

9.7 Bristol-Myers Squibb 9.8 Celgene 9.9 Eisai Co., Ltd. 9.10 Eli Lilly & Co

9.11 ImClone Systems Inc. (a subsidiary of Eli Lilly & Co) 9.12 Exelixis 9.13 GlaxoSmithKline 9.14 Merck & Co 9.15 Millennium Pharmaceuticals (Subsidiary of Takeda Oncology Company) 9.16 Novartis Pharmaceuticals 9.17 Onyx Pharmaceuticals 9.18 Pﬁzer Inc. 9.19 Roche 9.20 Sanoﬁ 9.21 Teva Pharmaceuticals Industries

Chap t e r 10 Exp e rt O p inio n 10.1 Dr John Marshall, Clinical Director of Oncology, Georgetown University Hospital 10.2 Dr Anderson Ryan, Senior Group Leader at Gray Institute of Radiation, Oncology and Biology, at the University of Oxford 10.3 Dr Ben Anderson, Professor of Surgery at the University of Washington & Chair of the Breast Health Global Initiative

PDFmyURL lets you convert a complete website to PDF automatically!

L is t o f T ab le s

Table 2.1.1.1 Major Drugs in Blood Cancer Market Table 2.1.2.1 Major Bone Cancer Drugs in the Market Table 2.1.3.1 Major Brain Cancer Drugs in Market Table 2.1.4a Breast Cancer Incidences in US & UK Table 2.1.4b Major Breast Cancer Drugs in Market Table 2.1.5 Major Gastrointestinal Cancer Drugs in Market Table 2.1.6 Major Endocrine Cancer Drugs in Market Table 2.1.7 Major Eye Cancer drugs In the Market Table 2.1.8 Major Genitourinary Cancers Cancer drugs In the Market Table 2.1.9 Major Gynaecologic Cancer drugs In the Market Table 2.1.10a Head & Neck Incidences in Asian Region - 2008 Table 2.1.10b Major Head and Neck Cancer Drugs in the Market Table 2.1.11 Major Respiratory Cancer Drugs in the Market Table 2.1.12 Major Skin Cancer Drugs in the Market Table 4.1 Type of Cancer Surgeries

Table 4.3 Type of Radiation Therapy Table 4.5 Types of Immunotherapy Table 4.6 Types of Hormone Therapy Table 4.7 Type or Ways of Hyperthermia Treatment Table 4.8 Type of Stem Cell Transplant Table 4.9.2 Type of Laser Treatments Table 5.1.a: Global Targeted Therapy Market for Cancer Treatment: 2008-2012 Table 5.1.b: Global Targeted Therapy Market for Cancer Treatment: 2013-2023 PDFmyURL lets you convert a complete website to PDF automatically!

Table 5.1.1.a: 2011 - 2012 Rituxan Sales Geographic Breakdown ($ bn) Table 5.1.1.b: Rituxan Oncology Sales: 2008-2012 Table 5.1.1.c: Rituxan Sales & Forecast: 2013-2023 Table 5.1.2.a: Herceptin Sales: 2008-2012 Table 5.1.2.b: 2011 - 2012 Herceptin Sales Geographic Breakdown ($ bn) Table 5.1.2.c: Herceptin Sales & Forecast: 2013-2023

Table 5.1.3.a: Avastin Sales: 2008-2012 Table 5.1.3.b: 2011 - 2012 Avastin Sales Geographic Breakdown ($ bn) Table 5.1.3.c: Avastin Sales & Forecast: 2013-2023 Table 5.1.4.a: Gleevec Sales: 2008-2012 Table 5.1.4.b: 2011 - 2012 Gleevec Sales Geographic Breakdown ($ bn) Table 5.1.4.c: Gleevec Sales & Forecast: 2013-2023 Table 5.1.5.a: Velcade Sales: 2008-2012 Table 5.1.5.b: 2011 - 2012 Velcade Sales Geographic Breakdown ($ bn) Table 5.1.5.c: Velcade Sales & Forecast: 2013-2023 Table 5.1.6.a: Tarceva Sales: 2008-2012 Table 5.1.6.b: 2011 - 2012 Tarceva Sales Geographic Breakdown ($/m) Table 5.1.6.c: Tarceva Sales & Forecast: 2013-2023

Table 5.1.7.a: Sutent Sales: 2008-2012 Table 5.1.7.b: Sutent Sales & Forecast: 2013-2023 Table 5.1.8.a: Sprycel Sales: 2008-2012 Table 5.1.8.b: 2011 - 2012 Sprycel Sales Geographic Breakdown ($ m) Table 5.1.8.c: Sprycel Sales & Forecast: 2013-2023 Table 5.1.9.a: Nexavar Sales: 2008-2012 ($/bn) PDFmyURL lets you convert a complete website to PDF automatically!

Table 5.1.9.b: Nexavar Sales & Forecast: 2013-2023 Table 5.1.10.a: Tasigna Sales: 2008-2012 Table 5.1.10.b: 2011 - 2012 Tasigna Sales Geographic Breakdown ($ m) Table 5.1.10.c: Tasigna Sales & Forecast: 2013-2023 Table 5.1.11.a: Afinitor Sales: 2008-2012 Table 5.1.11.b: 2011 - 2012 Afinitor Sales Geographic Breakdown ($ m) Table 5.1.11.c: Afinitor Sales & Forecast: 2013-2023 Table 5.1.12.a: Xgeva Sales: 2008-2012 Table 5.1.12.b: 2011 - 2012 Xgeva Sales Geographic Breakdown ($ m) Table 5.1.12.c: Xgeva Sales & Forecast: 2013-2023 Table 5.1.13.a: Yervoy Sales: 2011-2012 Table 5.1.13.b: 2011 - 2012 Yervoy Sales Geographic Breakdown ($ m) Table 5.1.13.c: Yervoy Sales & Forecast: 2013-2023 Table 5.1.14.a: Erbitux Sales BMS: 2008-2012 Table 5.1.14.b: Erbitux Sales Merck KGaA: 2008-2012

Table 5.1.14.c: Erbitux Sales & Forecast: 2013-2023 Table 5.2.a: Global Chemotherapy Market for Cancer Treatment: 2008-2012 Table 5.2.b Market Size & Forecast – Chemotherapy Market 2013-2023 Table 5.2.1.a: Alimta Sales: 2008-2012 Table 5.2.1.b: 2011 - 2012 Alimta Sales Geographic Breakdown ($ bn) Table 5.2.1.c: Alimta Sales & Forecast: 2013-2023 Table 5.2.2.a: Xeloda Sales: 2008-2012 Table 5.2.2.b: 2011 - 2012 Xeloda Sales Geographic Breakdown ($ m) Table 5.2.2.c: Xeloda Sales & Forecast: 2013-2023 Table 5.2.3.a: Eloxatin Sales: 2008-2012 PDFmyURL lets you convert a complete website to PDF automatically!

Table 5.2.3.b: 2011 - 2012 Eloxatin Sales Geographic Breakdown ($ bn) Table 5.2.3.c: Eloxatin Sales & Forecast: 2013-2023 Table 5.2.4.a: Temodar Sales: 2008-2012 Table 5.2.4.b: Temodar Sales & Forecast: 2013-2023 Table 5.2.5.a: Vidaza Sales: 2008-2012 Table 5.2.5.b: Vidaza Sales & Forecast: 2013-2023 Table 5.2.6.a: Taxotere Sales: 2008-2012 Table 5.2.6.b: 2011 - 2012 Taxotere Sales Geographic Breakdown ($ bn) Table 5.2.6.c: Taxotere Sales & Forecast: 2013-2023 Table 5.2.7.a: Treanda Sales: 2008-2012

Table 5.2.7.b: Treanda Sales & Forecast: 2013-2023 Table 5.3 Market Size & Forecast – Immunotherapy Market 2013-2023 Table 5.3.1.a: Revlimid Sales: 2008-2012 Table 5.3.1.b: Revlimid Sales & Forecast: 2013-2023 Table 5.3.2.a: Gardasil Sales: 2008-2012 Table 5.3.2.b: Gardasil Sales & Forecast: 2013-2023 Table 5.3.3.a: Zometa Sales: 2008-2012 Table 5.3.3.b: 2011 - 2012 Zometa Sales Geographic Breakdown ($/m) Table 5.3.3.c: Zometa Sales & Forecast: 2013-2023 Table 5.3.4.a: Global Hormone Therapy Market for Cancer Treatment: 2008-2012 Table 5.3.4.b Market Size & Forecast – Hormone Therapy Market 2013-2023 Table 5.4.1.a: Faslodex Sales: 2008-2012 Table 5.4.1.b: 2011 - 2012 Faslodex Sales Geographic Breakdown ($ m)

Table 5.4.1.c: Faslodex Sales & Forecast: 2013-2023

PDFmyURL lets you convert a complete website to PDF automatically!

Table 5.4.2.a: Zoladex Sales: 2008-2012 T able5.4.2.b: 2011 - 2012 Zoladex Sales Geographic Breakdown ($ m) Table 5.4.2.c: Zoladex Sales & Forecast: 2013-2023able Table 5.4.3.a List of generic Anastrozole manufacturing companies in 1 mg tablet type Table 5.4.3.b: Arimidex Sales: 2008-2012 Table 5.4.3.c: 2011 - 2012 Arimidex Sales Geographic Breakdown ($ m) Table 5.4.3.d: Arimidex Sales & Forecast: 2013-2023 Table 5.4.4.a: Casodex Sales: 2008-2012 Table 5.4.4.b: 2011 - 2012 Casodex Sales Geographic Breakdown ($ m) Table 5.4.4.c: Casodex Sales & Forecast: 2013-2023 Table 5.4.5.a: Sandostatin Sales: 2008-2012

Table 5.4.5.b: 2011 - 2012 Sandostatin Sales Geographic Breakdown ($ m) Table 5.4.5.c: Sandostatin Sales & Forecast: 2013-2023 Table 6.1a Oncology Drug – Recent Approvals Table 6.1b Oncology Drug Pipeline – Top 5 Late-stage Cancer Drugs Table 6.1c Oncology Drug Pipeline – Top 10 Experimental Cancer Drugs Table 6.1d Oncology Drug Pipeline – Cancer Drugs Failures Table 7.1 Key Emerging Countries Population Forecasts, 2013, 2018 & 2023 Table 7.2 Key Cancer Drugs Patent Expirations Table 7.3 Revenue loss due to Generic Competition Table 7.4 Future Revenue loss due to Generic Competition Table 8.a: The Global Oncology Market Forecast 2013 -2023, by Country ($ bn) Table 8.b Key Countries CAGR 2013-2023 (%) Table 8.c Estimated Global Oncology Market Share for Selected Countries 2013, 2018 and 2023 (%) Table8.d: Total Healthcare Spending and Healthcare Expenditure per Capita 2011, Sample countries PDFmyURL lets you convert a complete website to PDF automatically!

($/p/a) Table 8.1.1: The US Oncology Market Forecast 2013-2023 ($bn) Table 8.1.2 Estimated Rates of Cancer in the US / Survival Rate 2012 Table 8.2.1: The UK Oncology Market Forecast 2013-2023 ($bn) Table 8.2.2: The UK's national CDF list Table 8.3.1: The French Oncology Market Forecast 2013-2023 ($ bn)

Table 8.4.1: The German Oncology Market Forecast 2013-2023 ($ bn) Table 8.4.2: Germany Cancer Statistics Table 8.5.1: The Spanish Oncology Market Forecast 2013-2023 ($ bn) Table 8.6.1: The Italian Oncology Market Forecast 2013-2023 ($ bn) Table 8.6.2: Percentage of patient access to oncology medicines by Italian region Table 8.6.3: Major cancer drug prices in Italy (INCORRECT CHART BELOW) Table 8.7.1: The Japanese Oncology Market Forecast 2013-2023 ($ bn) Table 8.8.1: The ROW Oncology Market Forecast 2013-2023 ($ bn) Table 8.2.2: BRIC Population, Healthcare Expenditure per Capita Table 8.2.3 Estimated Oncology Market Share for Selected Countries 2013, 2018 and 2023 (%) Table 9.1.1. Amgen Oncology Product overview Table 9.1.2. Amgen Oncology Product pipeline

Table 9.2.1 Arida Oncology Product overview Table 9.2.2 Product pipeline Table 9.3.1 Astellas Oncology Products Overview Table 9.3.2 Astellas Oncology Product Pipeline Table 9.4.1 AstraZeneca Oncology Product pipeline PDFmyURL lets you convert a complete website to PDF automatically!

Table 9.5.1 Bayer healthcare pharmaceuticals Oncology Product overview Table 9.5.2 Bayer healthcare pharmaceuticals Oncology Product pipeline Table 9.6.1 Boehringer Ingelheim Oncology Product overview Table 9.6.2 Boehringer Ingelheim Oncology Product pipeline Table 9.7.1 Bristol-Myers Squibb Oncology Products Overview Table 9.7.2 Bristol-Myers Squibb Oncology Pipeline Projects Table 9.8.1 Celgene oncology Product overview Table 9.8.2 Celgene oncology Product pipeline Table 9.9.1 Eisai Co., Ltd. Oncology Product overview Table 9.9.2 Eisai Co., Ltd. Oncology Product pipeline Table 9.10.1 Eli Lilly & Co oncology Products Overview

Table 9.10.2 Eli Lilly & Co oncology Pipeline Product Table 9.11.1 ImClone Systems Inc. Oncology Product pipeline Table 9.12.1 Exelixis Oncology Products Overview Table 9.12.2 Exelixis Oncology Pipeline Projects Table 9.13.1 GlaxoSmithKline Oncology Product overview Table 9.13.2 GlaxoSmithKline Oncology Product pipeline Table 9.13.3 GlaxoSmithKline Oncology Product Antigen-speciďŹ c cancer immunotherapeutic (ASCI) Table 9.14.1 Merck Oncology Products Overview Table 9.14.2 Merck Oncology Merck Pipeline Table 9.15.1 Millennium Pharmaceuticals Oncology Product overview Table 9.15.2 Millennium Pharmaceuticals Oncology Product pipeline Table 9.16.1 Novartis Pharmaceuticals Oncology product overview Table 9.16.2 Novartis Pharmaceuticals Oncology Product pipeline Table 9.17.1 Onyx Pharmaceuticals Oncology Product overview PDFmyURL lets you convert a complete website to PDF automatically!

Table 9.17.2 Onyx Pharmaceuticals Oncology Product pipeline Table 9.18.1 Pfizer Inc. Oncology Product overview Table 9.18.2 Pfizer Inc. Oncology Product Pipeline Table 9.19.1 Roche Oncology Products overview Table 9.19.2 Roche Oncology Product pipeline Table 9.20.1 Sanofi Oncology Product overview Table 9.20.2 Sanofi Oncology Product pipeline Table 9.21.1 Teva Pharmaceuticals Industries Oncology Product overview Table 9.21.2 Teva Pharmaceuticals Industries Oncology Product pipeline

L is t o f Fig ure s Figure 2.1.1.1 Blood Cancer Type – Incidences Figure 2.1.2.1: Global Breakdown of types of Bone Cancer Figure2.1.11 Global Market Size as per Lung Cancer Type – Incidences Figure 2.1.12 Global Market Size as per Skin Cancer Type – Incidences Figure2.2.1a Global Cancer Market as per Incidences Figure2.2.2a Global Cancer Market by Mortality & Survival Figure 5.1.a: Global Targeted Therapy Market for Cancer Treatment: 2008-2012 Figure 5.1.b: 2012 Targeted Therapy Market by Major Drugs Figure 5.1.c: 2012 Other Targeted Therapy Drugs Market Share Figure 5.1d: Global Targeted Therapy Market for Cancer Treatment: 2013-2023 Figure 5.1.1.a: 2012 Rituxan Sales Geographic Breakdown Figure 5.1.1.b: Rituxan Sales: 2008-2012 Figure 5.1.1.c: Rituxan Sales & Forecast: 2013-2023 Figure 5.1.2.1: Herceptin Sales: 2008-2012 PDFmyURL lets you convert a complete website to PDF automatically!

Figure 5.1.2.2: 2012 Herceptin Sales Geographic Breakdown Figure 5.1.2.3: Herceptin Sales & Forecast: 2013-2023 Figure 5.1.3.1: Avastin Sales: 2008-2012 Figure 5.1.3.2: 2012 Avastin Sales Geographic Breakdown Figure 5.1.3.3: Avastin Sales & Forecast: 2013-2023 Figure 5.1.4.1: Gleevec Sales: 2008-2012

Co mp anie s me nt io ne d in t his re p o rt ; Actavis Alkem Laboratories Ltd Ambrilia Biopharma Amgen Inc. Ariad Pharmaceuticals ArQule Astellas Pharma Astex Pharmaceuticals AstraZeneca Bayer Biocon Biogen BioXpress Bristol-Myers Squibb

Cadila Healthcare Cambridge University PDFmyURL lets you convert a complete website to PDF automatically!

Cancer Research Technology Limited Celgene Cell Therapeutics Inc. Celltrion Celon Labs Chugai Chugai Pharmaceutical Cipla Limited Daiichi Sankyo Company, Limited Debiopharm Eisai Inc.

Eli Lilly Fludara FujiďŹ lm Fujisawa Pharmaceutical Company Ltd Genentech Genmab Gilead Sciences GlaxoSmithKline Glenmark Pharmaceuticals Ltd ImClone LLC Janssen Pharmaceuticals, Inc. Johnson & Johnson Kyowa Hakko Kirin PDFmyURL lets you convert a complete website to PDF automatically!

Lupin Laboratories Ltd Lyka Labs Limited Medicare Remedies Pvt Ltd Merck & Co., Inc. Micromet, Inc. Millennium Pharmaceuticals Miracalus Pharma Pvt Ltd Mylan National Institute for Health and Clinical Excellence Neon Laboratories Ltd Newcastle University Northern Institute for Cancer Research Novartis Onconova Therapeutics Ono Pharmaceutical Onyx Pharmaceutical Otsuka Pharmaceuticals Oxford BioMedica Oxford University PďŹ zer Inc.

Pharmacyclics Plexxikon Inc. Regeneron Pharmaceuticals Roche SanoďŹ -Aventis PDFmyURL lets you convert a complete website to PDF automatically!

Seattle Genetics Sun Pharmaceutical Industries Ltd SuperGen Synthon Taj Pharmaceuticals Ltd Takeda Teva Pharmaceuticals UCLA Yamanouchi Pharmaceutical Company Ltd Zenyaku Kogyo Co. Ltd

To o rd e r t his re p o rt : T he Cance r D rug s & T re at me nt s Marke t - D at a, Analys is & Fo re cas t s t o 20 23' ht t p ://www.re p o rt linke r.co m/p 0 1889 380 /T he - Cance r- D rug s - - T re at me nt s - Marke t - - D at a- Analys is - - Fo re cas t s - t o 20 23'.ht ml#ut m_s o urce = p rne ws wire & ut m_me d ium= p r& ut m_camp aig n= D rug _and _Me d icat io n

__________________________ Co nt act Clare : clare @ re p o rt linke r.co m US: (339 )- 36 8- 6 0 0 1 Int l: + 1 339 - 36 8- 6 0 0 1

SOURCE Reportlinker

PDFmyURL lets you convert a complete website to PDF automatically!

RELATED LINKS http://www.reportlinker.com













